摘要
目的探讨曲妥珠单抗联合氟维司群治疗晚期乳腺癌患者疗效、安全性及对预后的影响。方法回顾性分析2016年6月至2017年4月于我院诊疗人表皮生长因子受体-2(HER2)阳性,雌激素受体(HR)+型晚期乳腺癌绝经女性患者60例作为研究对象,2组患者均已接受乳腺癌的常规手术,化疗和(或)放疗,靶向治疗(曲妥珠单抗)及内分泌治疗(他莫昔芬),其中,30例为使用曲妥珠单抗治疗的基础上联合氟维司群进行内分泌治疗的患者,作为研究组,同时期采用氟维司群内分泌治疗的30例患者作为对照组,2组患者均治疗6个月,6个月后2组均给予曲妥珠单抗和氟维司群的治疗。比较2组患者的治疗效果、不良反应、乳腺癌扩增性抗原1(AIB1)、激活转录因子3(ATF3)以及生活质量之间的差异;随访3年,对比2组术后生存期。结果①通过对所有患者的随访,随访率为97%(58/60),观察组患者的总生存期(OS)及无进展生存期(PFS)均显著高于对照组(P<0.05);②2组患者出现肝功能异常、低热、乏力等差异无统计学意义(P>0.05);③经过治疗后,2组患者的AIB1、ATF3水平显著降低,且观察组患者AIB1、ATF3水平显著低于对照组(P<0.05);④经过治疗后,2组患者的生理功能、生理职能、躯体疼痛、一般健康、精力、社会功能、情感职能、心理健康、总分显著升高,且观察组患者的生理功能、生理职能、躯体疼痛、一般健康、精力、社会功能、情感职能、心理健康、总分等均高于对照组(P<0.05);⑤治疗后,2组患者治疗客观有效率和疾病控制率差异有统计学意义,相较于对照组,研究组均较高(P<0.05)。结论晚期乳腺癌患者采用曲妥珠单抗治疗基础上联合氟维司群治疗,可以改善患者的AIB1、ATF3水平,提升患者的临床治疗效果和生活质量。
Objective To investigate the efficacy,safety and prognosis of trastuzumab combined with fluvestrant in the treatment of advanced breast cancer.Methods A retrospective analysis was performed on 60 postmenopausal women with HER2-positive HR+metastatic breast cancer treated in our hospital from June 2016 to April 2017.All patients had received conventional chemotherapy.Thirty patients who were treated with trastuzumab and fluvistrane were selected as the study group.The other 30 patients who were treated with trastuzumab were selected as the control group.After 6 months for treating,the two groups were given tamoxifen and fluvistrane continuous treating respectively.The differences of the treatment effect,prognosis and survival,adverse reactions,AIB1,ATF3 and quality of life between the two groups were compared.The two groups were followed up for 3 years,and the postoperative survival was compared.Results①Through the follow-up of all patients,the follow-up rate was 97%(58/60),and the OS and PFS of the observation group were significantly higher than those of the control group(P<0.05);②There were no significant differences in abnormal liver function,low fever,fatigue and so on between the two groups(P>0.05);③After treatment,the levels of AIB1 and ATF3 in the two groups were significantly decreased,and the levels of AIB1 and ATF3 in the observation group were significantly lower than those in the control group(P<0.05);④After treatment,the physiological function,physiological function,physical pain,general health,energy,social function,emotional function,mental health,and total scores of the patients in the two groups significantly increased,and those in observation group were significantly higher than those in the control group(P<0.05);⑤After treatment,there were significant differences in the objective effective rate and disease control rate between the two groups,which in the study group were higher than those in the control group(P<0.05).Conclusion Trastuzumab combined with fulvestrant therapy in patients
作者
于磊
张华一
刘美亚
梁帅
杜欢
Yu Lei;Zhang Huayi;Liu Meiya;Liang Shuai;Du Huan(Deparment of Breast Surgery,Cancer Hospital of Chinese Academy of Sciences Shanxi Hospital Shanxi Cancer Hospital,Taiyuan 030013,China)
出处
《山西医药杂志》
CAS
2024年第1期3-8,共6页
Shanxi Medical Journal
